Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The Fas-associated death domain protein suppresses activation of NF-κB by LPS and IL-1β
Douglas D. Bannerman, Joan C. Tupper, James D. Kelly, Robert K. Winn, John M. Harlan
Douglas D. Bannerman, Joan C. Tupper, James D. Kelly, Robert K. Winn, John M. Harlan
View: Text | PDF
Article

The Fas-associated death domain protein suppresses activation of NF-κB by LPS and IL-1β

  • Text
  • PDF
Abstract

Activation of NF-κB by bacterial LPS promotes the upregulation of proinflammatory cytokines that contribute to the pathogenesis of Gram-negative septic shock. LPS activation of NF-κB is dependent upon the interaction of two death domain–containing (DD-containing) proteins, MyD88 and IL-1 receptor–associated kinase IRAK. Another DD-containing protein, Fas-associated death domain (FADD), also binds MyD88 through respective DD-DD interactions. Although FADD has been classically described as a proapoptotic signaling molecule, several reports have implicated a role for FADD in mediating NF-κB activation. In the present report, we investigated whether FADD could mediate LPS activation of NF-κB. Overexpression of FADD blocked LPS-induced NF-κB activation, whereas absence of FADD enhanced activation of NF-κB by LPS. Further, LPS-induced expression of two NF-κB–dependent gene products, IL-6 and KC, was enhanced in FADD–/– mouse embryo fibroblasts (MEFs) compared with wild-type. This increase in NF-κB activity correlated with enhanced IκB degradation. FADD–/– MEFs were also resistant to NF-κB activation induced by IL-1β. Finally, reconstitution of full-length FADD in the FADD–/– MEFs completely reversed the enhanced activation of NF-κB elicited by either LPS or IL-1β. Together, these data indicate that FADD negatively regulates LPS- and IL-1β–induced NF-κB activation and that this regulation occurs upstream of IκB degradation.

Authors

Douglas D. Bannerman, Joan C. Tupper, James D. Kelly, Robert K. Winn, John M. Harlan

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Reconstitution of FADD reverses the enhanced NF-κB activation and NF-κB–...
Reconstitution of FADD reverses the enhanced NF-κB activation and NF-κB–dependent gene expression in FADD–/– MEFs exposed to LPS or IL-1β. Lysates derived from FADD–/– MEFs stably transfected with either GFP vector alone or FADD were immunoblotted with anti-human FADD antibody to confirm expression (a). Molecular mass (in kDa) is indicated. In other experiments, FADD–/– MEFs expressing either GFP or FADD were treated for 4.5 hours with medium, LPS (100 ng/ml), or mIL-1β (10 ng/ml), lysed, and assayed for luciferase activity (b). Alternatively, MEFs were treated for 12 hours and the culture supernatants analyzed for IL-6 (c) or KC (d). Vertical bars represent mean (± SE) luciferase activity in arbitrary units (b) or pg/ml (c and d). *Significantly decreased compared with GFP-expressing cells exposed to the same treatment.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts